{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&_properties=tablingMember.label,tablingMember,answer,answeringDeptShortName,answer.dateOfAnswer,questionText&uin=211732&_sort=-answer.isMinisterialCorrection", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?_properties=tablingMember.label,tablingMember,answer,answeringDeptShortName,answer.dateOfAnswer,questionText&uin=211732&_sort=-answer.isMinisterialCorrection", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&_properties=tablingMember.label,tablingMember,answer,answeringDeptShortName,answer.dateOfAnswer,questionText&uin=211732&_metadata=all&_sort=-answer.isMinisterialCorrection", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&_properties=tablingMember.label,tablingMember,answer,answeringDeptShortName,answer.dateOfAnswer,questionText&uin=211732&_sort=-answer.isMinisterialCorrection", "isPartOf" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_properties=tablingMember.label,tablingMember,answer,answeringDeptShortName,answer.dateOfAnswer,questionText&uin=211732&_sort=-answer.isMinisterialCorrection", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?_properties=tablingMember.label,tablingMember,answer,answeringDeptShortName,answer.dateOfAnswer,questionText&uin=211732&_sort=-answer.isMinisterialCorrection", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&_properties=tablingMember.label,tablingMember,answer,answeringDeptShortName,answer.dateOfAnswer,questionText&uin=211732&_sort=-answer.isMinisterialCorrection", "type" : "http://purl.org/linked-data/api/vocab#ListEndpoint"} , "items" : [{"_about" : "http://data.parliament.uk/resources/100721", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100721/answer", "answerText" : {"_value" : "
The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>
<\/p>
<\/p>
<\/p>
£ million<\/em><\/p> <\/p> 2009-10<\/p><\/td> 2010-11<\/p><\/td> 2011-12<\/p><\/td> 2012-13<\/p><\/td> 2013-14<\/p><\/td><\/tr> Asthma<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.3<\/p><\/td> 1.5<\/p><\/td> 0.8<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 2.6<\/p><\/td> 3.4<\/p><\/td> 2.4<\/p><\/td> 3.4<\/p><\/td> 3.8<\/p><\/td><\/tr> Total<\/p><\/td> Motor Neurone Research<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 7.0<\/p><\/td> 7.5<\/p><\/td> 4.2<\/p><\/td> 4.1<\/p><\/td> 3.6<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 0.5<\/p><\/td><\/tr> Total<\/p><\/td> 7.3<\/p><\/td> 7.8<\/p><\/td> 5.0<\/p><\/td> 5.5<\/p><\/td> 5.1<\/p><\/td><\/tr> Osteoporosis<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 6.2<\/p><\/td> 5.4<\/p><\/td> 5.1<\/p><\/td> 4.6<\/p><\/td> 5.9<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.3<\/p><\/td> 0.7<\/p><\/td> 0.8<\/p><\/td> 1.3<\/p><\/td> 1.8<\/p><\/td><\/tr> Total<\/p><\/td> 6.5<\/p><\/td> 6.1<\/p><\/td> 6.0<\/p><\/td> 6.3<\/p><\/td> 8.7<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p> <\/p> <\/p> <\/p> Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p> <\/p> <\/p> <\/p> Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100721/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Osteoporosis"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much from the publich purse has been spent on research into osteoporosis in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211732"}
, {"_about" : "http://data.parliament.uk/resources/1047083", "AnsweringBody" : [{"_value" : "Home Office"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1047083/answer", "answerText" : {"_value" : " To be eligible for settled status under the EU Settlement Scheme, applicants will generally be required to demonstrate continuous residence in the UK for a minimum of five years in one of the eligible categories. This reflects the continuous residence criteria for the acquisition of \u2018permanent residence\u2019 under the Free Movement Directive, and the approach agreed with the European Union in the draft Withdrawal Agreement.<\/p> Should an applicant not be immediately eligible for settled status, and instead be granted pre-settled status (five years\u2019 limited leave to remain), they must continue to meet these continuous residence criteria in order to qualify for settled status. This will be made clear to them when they are granted pre-settled status.<\/p> Those granted pre-settled status who are not eligible for settled status before the expiry of their five years\u2019 limited leave to remain, owing to excess absence(s) from the UK, will have the option of applying for leave to remain under the new skills-based immigration system.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4048", "label" : {"_value" : "Biography information for Caroline Nokes"}
}
, "answeringMemberConstituency" : {"_value" : "Romsey and Southampton North"}
, "answeringMemberPrinted" : {"_value" : "Caroline Nokes"}
, "dateOfAnswer" : {"_value" : "2019-02-01", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "211733"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-02-01T14:07:33.877Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "1"}
, "answeringDeptShortName" : {"_value" : "Home Office"}
, "answeringDeptSortName" : {"_value" : "Home Office"}
, "date" : {"_value" : "2019-01-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Immigration: EU Nationals"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for the Home Department, what provision he plans to make in the EU Settlement scheme for those who have held pre-settled status for five years but cannot qualify for settled status due to excessive absences.", "registeredInterest" : {"_value" : "true", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4120", "label" : {"_value" : "Biography information for Kate Green"}
}
, "tablingMemberConstituency" : {"_value" : "Stretford and Urmston"}
, "tablingMemberPrinted" : [{"_value" : "Kate Green"}
], "uin" : "211732"}
], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 2, "type" : "http://purl.org/linked-data/api/vocab#Page"}
}
<\/td> 22.2 <\/del>6.6<\/ins><\/p><\/td>17.5 <\/del>5.3<\/ins><\/p><\/td>17.2<\/del> 4.5<\/ins><\/p><\/td>19.4<\/del> 3.6<\/ins><\/p><\/td>18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>24.8<\/del> 9.2<\/ins><\/p><\/td>21.0<\/del> 8.8<\/ins><\/p><\/td>19.9<\/del> 7.2<\/ins><\/p><\/td>24.3 <\/del>8.5<\/ins><\/p><\/td>23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>